Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Broadtree Partners Raises Multi-Asset Continuation Fund

    William Blair acted as exclusive financial advisor to Broadtree Partners, LLC in connection with its successful closing of a multi-asset continuation fund with approximately $240 million of total commitments.

    Read more

  • Aktis Oncology, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Aktis Oncology, Inc. (AKTS $18.60), a clinical-stage radiopharmaceuticals company that is focused on the actinium-225 payload.

    Read more

  • Social Security and Medicare What Seniors Need to Know About Two Big Decisions

    As you enter your 60s and reach retirement age, you have some big decisions to make that can significantly affect your finances and quality of life.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures